Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Regulus Therapeutics Inc. (RGLS)

1.47   -0.06 (-3.92%) 01-27 16:00
Open: 1.5679 Pre. Close: 1.53
High: 1.59 Low: 1.44
Volume: 64,821 Market Cap: 25(M)

Technical analysis

as of: 2023-01-27 4:47:32 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.91     One year: 2.23
Support: Support1: 1.29    Support2: 1.08
Resistance: Resistance1: 1.63    Resistance2: 1.91
Pivot: 1.47
Moving Average: MA(5): 1.48     MA(20): 1.45
MA(100): 1.6     MA(250): 1.99
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 56.2     %D(3): 61.3
RSI: RSI(14): 50.6
52-week: High: 3.7  Low: 0.23
Average Vol(K): 3-Month: 47 (K)  10-Days: 40 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RGLS ] has closed above bottom band by 48.6%. Bollinger Bands are 48.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.59 - 1.6 1.6 - 1.6
Low: 1.42 - 1.43 1.43 - 1.44
Close: 1.46 - 1.47 1.47 - 1.48

Company Description

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Headline News

Fri, 13 Jan 2023
Regulus Reports Inducement Grant Under Nasdaq Listing Rule ... - PR Newswire

Mon, 09 Jan 2023
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics - Yahoo Finance

Mon, 12 Dec 2022
Regulus Therapeutics Announces Resignation of Board Member - PR Newswire

Thu, 10 Nov 2022
Regulus Therapeutics Reports Third Quarter 2022 Financial Results ... - PR Newswire

Thu, 27 Oct 2022
Regulus Therapeutics Announces Poster Presentation at ASN ... - PR Newswire

Mon, 12 Sep 2022
Regulus Therapeutics Announces Positive Topline Safety and ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 17 (M)
Shares Float 15 (M)
% Held by Insiders 3.6 (%)
% Held by Institutions 51.3 (%)
Shares Short 233 (K)
Shares Short P.Month 285 (K)

Stock Financials

EPS -0.29
EPS Est Next Qtl -0.16
EPS Est This Year -0.96
EPS Est Next Year -0.41
Book Value (p.s.) 2.35
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -37.2
Return on Equity (ttm) -83.5
Qtrly Rev. Growth 0
Gross Profit (p.s.) -1.06
Sales Per Share 0
EBITDA (p.s.) -1.68
Qtrly Earnings Growth 0
Operating Cash Flow -27 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio -5.22
PEG Ratio -0.1
Price to Book value 0.62
Price to Sales 0
Price to Cash Flow -0.92

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2018-10-03
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.